$RGEN (Repligen Corporation)

$RGEN {{ '2016-05-19T13:51:29+0000' | timeago}} • Announcement

$RGEN said it anticipates the proceeds from the offering to be about $100MM, excluding any exercise of underwriters' option to buy additional $15MM of Notes. The company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

$UNH {{ '2018-01-17T18:35:18+0000' | timeago}} • Webcast

For 2018, health insurance provider UnitedHealth expects its profits between $16.7-17.3Bil. $UNH expects its premium revenues to reduce $400-500MM due to regulatory changes in Affordable Care Act. The company also plans to invest $200-300MM this year in artificial intelligence, data analytics etc. which would improve its engagement with customers.

$UNH {{ '2018-01-17T18:34:42+0000' | timeago}} • Webcast

UnitedHealth's 2017 medical care ratio increased 90 basis points to 82.1% vs. last year. Medical care ratio shows how much money is spent on healthcare from the premiums received by the health insurer. $UNH expects its 2018 medical care ratio to come around 81.5% plus or minus 50 basis points.

$UNH {{ '2018-01-17T18:34:08+0000' | timeago}} • Webcast

UnitedHealth's 4Q profits spiked to $3.62Bil whereas revenue was up 9% to $52.06Bil. $UNH's Health Insurance segment brings in more revenues, but Optum segment contributed more to its profits. Optum's profits were up 22% reaching $2.2Bil in 4Q. For 2017, the company reported a non-cash tax benefit of $1.22 per share due to tax reforms.

$UNH {{ '2018-01-17T13:48:18+0000' | timeago}} • Announcement

Largest US health insurer UnitedHealth's profits more than doubled in the fourth quarter to $3.61Bil due to tax benefits. $UNH also crossed $200Bil mark in revenues for FY17. The company now expects to save $1.7Bil in FY18 due to tax reforms. For 2018, the health insurer expects GAAP EPS between $11.65-11.95 and non-GAAP EPS between $12.30-12.60.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$UNH {{ '2018-01-16T17:58:43+0000' | timeago}} • Infographic

$UNH UnitedHealth Group Incorporated Earnings AlphaGraphic: Q4 2017 Highlights

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$SGEN {{ '2017-12-11T16:30:10+0000' | timeago}} • Announcement

$SGEN and $BMY highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) in relapsed or refractory classical Hodgkin lymphoma (HL).

$ANTM {{ '2017-12-11T14:59:25+0000' | timeago}} • Infographic

At a time when the US health insurance sector stares at a rise in premium prices, amid the government’s move to repeal the Individual Mandate clause, an analysis shows that major players in the sector registered consistent revenue growth over the past ten years. $ANTM $UNH $AET $HUM $CI

$AGN {{ '2017-12-05T18:08:04+0000' | timeago}} • Announcement

Revance Therapeutics reported positive data for RT002, an injectable drug which would treat glabellar or frown lines. With positive results from the two Phase 3 trials, $AGN's rival plans to complete the third Phase 3 trial in 2H18 and file for FDA approval in 1H19, and introduce the competitive drug for Allergan's Botox in the U.S. in 2020.

$RGEN {{ '2017-11-07T15:02:00+0000' | timeago}} • Announcement

$RGEN extended a long-term supply agreement with Purolite Life Sciences for the manufacture of Protein A ligands at Repligen’s facilities in Waltham, MA and Lund, Sweden. $RGEN will supply Protein A ligands to Purolite through November 2022, with an option for renewal through 2025.

$AGN {{ '2017-11-03T20:08:36+0000' | timeago}} • Announcement

$AGN, which was criticized by the Federal Court recently on its Restasis deal, narrowed its revenue outlook for FY17. Allergan also widened its GAAP loss from the previous estimate, reflecting the generics competition and the potential patent losses. With regards to the Federal Court's decision on Restasis drug, the company had filed an appeal.

$AGN {{ '2017-11-03T19:30:46+0000' | timeago}} • Announcement

Despite an increase in revenue, $AGN swung to a loss in 3Q17, hurt by impairment charges related to its Restasis drug and Teva stake holding. Net loss was $4.03Bil or $12.07 per share versus net income of $15.2Bil or $38.58 per share a year ago. Revenue rose 11% to $4.03Bil, helped by the sales growth in drugs like Botox and Juvederm collection.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, January 16 2018 - 1:45pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
SGMO (Sangamo Biosciences Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
RGEN (Repligen Corporation)
Thursday, November 9 2017 - 1:30pm
QGEN (Qiagen NV)
Tuesday, November 7 2017 - 2:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
TECH (Bio-Techne Corp.)
Tuesday, October 31 2017 - 1:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
UNH (UnitedHealth Group Incorporated)
Tuesday, October 17 2017 - 12:45pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, August 9 2017 - 9:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
TECH (Bio-Techne Corp.)
Tuesday, August 8 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
RGEN (Repligen Corporation)
Thursday, August 3 2017 - 12:31pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm

AlphaGraphics you may like